Navigation Links
24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination
Date:3/5/2010

Microbial contamination is the third leading cause of mortality in the U.S., according to the Centers for Disease Control (CDC).

Charleston, SC (PRWEB) March 5, 2010 -- Today’s hospitals have an increasingly dangerous and costly problem. The culprit…Hospital Acquired Infections (HAIs) and they have generated much attention over the last decade. Studies have shown that up to 70% of HAIs are preventable with proper infection control, according to a Nurse Liaison for 24x7 Infection Control, Inc.    

A totally new (to the public) antimicrobial line named Goldshield®™ is a revolutionary product that, through independent studies it was demonstrated to eradicate germs on contact and inhibit their growth. Invented and patented by Emory University, Goldshield®™ is a system of products which includes an antimicrobial that is the first, and only, water-stabilized, non-toxic, non-leaching, environmentally benign solution providing a durable shield against microbial contamination, including mold, mildew and fungi.

Goldshield®™ offers an EPA-registered solution to combat dangerous microbial contamination in virtually every setting including hospitals, outpatient clinics, physicians offices, assisted living facilities, skilled nursing facilities, schools, colleges, athletic clubs, gymnasiums, spas, police departments, emergency medical services, fire departments, correctional institutions, the hospitality industry and commercial laundry facilities, to name a few.

Independent studies conducted at hospitals and universities have demonstrated that Goldshield® is a broad-spectrum bactericide, algaecide and fungicide. In these studies, it has been proven effective against Staphylococcus aureus (Staph), Methicillin-resistant Staphylococcus aureus (MRSA); including HA-MRSA (Healthcare-associated MRSA) and CA-MRSA (community- associated MRSA), Salmonella, E.coli, VRE (Vancomycin-Resistant Enterococci, and other hardy Gram (+) and Gram (-) bacteria. In a recent study in accordance with ASTM (American Society for Testing and Materials) protocols for virucidal efficacy on inanimate surfaces, Goldshield®™ was proven effective against Influenza A as a surrogate for H1N1.

Sharon Harper, an OR nurse and retired, Navy Infection Control Officer, stated, “I have seen the results and can appreciate why Goldshield®™ is so unique. In my opinion, the most exciting use of this new antimicrobial is via a “Bio-Vapor” Steam Cleaning System. This method allows Goldshield®™ to adhere in every ‘nook and cranny’! My mission as the nurse liaison for 24x7 Infection Control, Inc. is to inform government agencies, schools, hospitals, assisted living and long-term care communities that Goldshield®™ is now available.”

The parent company, AP Goldshield LLC is located in the United States, Israel, Asia, and Europe. 24x7 Infection Control, Inc. is an Authorized Distributor for Goldshield®™.

To find out more, please visit www.24x7infectioncontrol.com

Contact:                           
Sharon Harper RN, MSN                                         
LCDR/USN/RET
Sharon (at) 24x7infectioncontrol (dot) com
843-696-6830

###

Read the full story at http://www.prweb.com/releases/NEW/ANTIMICROBIAL/prweb3688064.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
2. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
3. Computers help chemists fight emerging infections
4. Infection contributes to the high rates of oropharyngeal cancers
5. Jefferson immunology researchers halt lethal rabies infection in brain
6. SIV infection of natural hosts provides new insights into HIV disease complexity
7. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
8. Natural aorta grafts have few side effects for infection-prone patients
9. Common misdiagnosis: most women believe they have a yeast infection when they dont
10. Patient Safety Authority Board of Directors Names Infection Advisory Panel
11. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 
(Date:7/21/2017)... ... July 21, 2017 , ... The most common surgical techniques ... of life five years after injury, according to research presented today at the ... Canada. The study followed patients for five years following surgery. , “Orthopaedic surgeons ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid ... cancer that progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens ... reoccurrence and relapse. With such a challenging diagnosis that requires immediate action, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Remote ... which their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ ... remote participants for real-time collaboration and immediate decision-making requirements. While never sharing ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... about the introduction of bipartisan House and Senate legislation in support of providing ... Congresswoman Robin Kelly (D-IL) introduced H.R. 2408, the “Protecting Girls’ Access to Education ...
(Date:7/20/2017)... ... July 20, 2017 , ... There’s a lot of confusing lingo out ... are the same thing. But it’s crucial to understand both the differences and similarities ... to Kaixuan Liu, MD, PhD, founder and president of Atlantic Spine Center . ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... ROCKVILLE, Md. , July 13, 2017  New York ... watchers of pharmaceutical markets should be aware of.  From new ... These trends are detailed in a recently completed study, ... following: 1.  Age-Driven ... years, we have been aware of the impact the growing ...
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  Bayer has awarded grants totaling more than ... of its prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. ... Philadelphia and Uniformed Services University of the Health ... winners. Grant recipients were announced last night during a reception ... Congress, Berlin, Germany . ...
Breaking Medicine Technology: